Georgette Tanner

Georgette Tanner

Auto-generated profile, based on publicly available information

Georgette Tanner

Leeds Institute of Medical Research at St James’s, University of Leeds , Leeds

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in Nature
Verified
Journal Article
Closed access
PDF file
FBFloris P. Barthel
Floris P. Barthel
KJKevin C. Johnson
Kevin C. Johnson
FVFrederick S. Varn
Frederick S. Varn
AMAnzhela D. Moskalik
Anzhela D. Moskalik
GTGeorgette Tanner
Georgette Tanner
TCThe GLASS Consortium
The GLASS Consortium

8 March 2024 in Science Advances
Verified
Journal Article
Open access
FMFabio Marcuccio
Fabio Marcuccio
CCChalmers C. Chau
Chalmers C. Chau
GTGeorgette Tanner
Georgette Tanner
MEMarilena Elpidorou
Marilena Elpidorou
MFMartina A. Finetti
Martina A. Finetti
PAPaolo Actis
Paolo Actis
Single-cell RNA sequencing has revolutionized our understanding of cellular heterogeneity, but routine methods require cell lysis and fail to probe the dynamic trajectories responsible for cellular state transitions, which can only be inferred. Here, we present a nanobiopsy platform that enables the injection of exogenous molecules and multigenerational longitudinal cytoplasmic sampling from a single cell and its progeny. The technique is based on scanning ion conductance microscopy (SICM) and, as a proof of concept, was applied to longitudinally profile the transcriptome of single glioblastoma (GBM) brain tumor cells in vitro over 72 hours. The GBM cells were biopsied before and after exposure to chemotherapy and radiotherapy, and our results suggest that treatment either induces or selects for more transcriptionally stable cells. We envision the nanobiopsy will contribute to transforming standard single-cell transcriptomics from a static analysis into a dynamic assay.

4 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GTGeorgette Tanner
Georgette Tanner
DWDavid R. Westhead
David R. Westhead
ADAlastair Droop
Alastair Droop
LSLucy Stead
Lucy Stead
Intratumour heterogeneity provides tumours with the ability to adapt and acquire treatment resistance. The development of more effective and personalised treatments for cancers, therefore, requires accurate characterisation of the clonal architecture of tumours, enabling evolutionary dynamics to be tracked. Many methods exist for achieving this from bulk tumour sequencing data, involving identifying mutations and performing subclonal deconvolution, but there is a lack of systematic benchmarking to inform researchers on which are most accurate, and how dataset characteristics impact performance. To address this, we use the most comprehensive tumour genome simulation tool available for such purposes to create 80 bulk tumour whole exome sequencing datasets of differing depths, tumour complexities, and purities, and use these to benchmark subclonal deconvolution pipelines. We conclude that i) tumour complexity does not impact accuracy, ii) increasing either purity or purity-corrected sequencing depth improves accuracy, and iii) the optimal pipeline consists of Mutect2, FACETS and PyClone-VI. We have made our benchmarking datasets publicly available for future use.

7 February 2024 in Genome Biology
Verified
Journal Article
Open access
PDF file
GTGeorgette Tanner
Georgette Tanner
RBRhiannon Barrow
Rhiannon Barrow
SAShoaib Ajaib
Shoaib Ajaib
MAMuna Al-Jabri
Muna Al-Jabri
NANazia Ahmed
Nazia Ahmed
LSLucy Stead
Lucy Stead
Background: Glioblastoma (GBM) brain tumors lackingIDH1mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumors almost always fatally recur.Results: Using RNA sequencing data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumors, we identify two responder subtypes based on longitudinal changes in gene expression. In two thirds of patients, a specific subset of genes is upregulated from primary to recurrence (Up responders), and in one third, the same genes are downregulated (Down responders), specifically in neoplastic cells. Characterization of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms that are associated with distinct changes in the tumor microenvironment. In Up responders, recurrent tumors are enriched in quiescent proneural GBM stem cells and differentiated neoplastic cells, with increased interaction with the surrounding normal brain and neurotransmitter signaling, whereas Down responders commonly undergo mesenchymal transition. ChIP-sequencing data from longitudinal GBM tumors suggests that the observed transcriptional reprogramming could be driven by Polycomb-based chromatin remodeling rather than DNA methylation.Conclusions: We show that the responder subtype is cancer-cell intrinsic, recapitulated in in vitro GBM cell models, and influenced by the presence of the tumor microenvironment. Stratifying GBM tumors by responder subtype may lead to more effective treatment.

14 December 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
ADAlastair Droop
Alastair Droop
ABAlexander Bruns
Alexander Bruns
GTGeorgette Tanner
Georgette Tanner
NRNora Rippaus
Nora Rippaus
RMRuth Morton
Ruth Morton
LSLucy Stead
Lucy Stead

1 February 2025 in Neuro-Oncology
Verified
Journal Article
Open access
MTMorgan P H Thomas
Morgan P H Thomas
SAShoaib Ajaib
Shoaib Ajaib
GTGeorgette Tanner
Georgette Tanner
ABAndrew J Bulpitt
Andrew J Bulpitt
LSLucy Stead
Lucy Stead
Background: Glioblastoma (GBM) presents a significant clinical challenge due to its aggressive nature and extensive heterogeneity. Tumor purity, the proportion of malignant cells within a tumor, is an important covariate for understanding the disease, having direct clinical relevance or obscuring signal of the malignant portion in molecular analyses of bulk samples. However, current methods for estimating tumor purity are nonspecific and technically demanding. Therefore, we aimed to build a reliable and accessible purity estimator for GBM. Methods: We developed GBMPurity, a deep learning model specifically designed to estimate the purity of IDH-wild type primary GBM from bulk RNA-sequencing (RNA-seq) data. The model was trained using simulated pseudobulk tumors of known purity from labeled single-cell data acquired from the GBmap resource. The performance of GBMPurity was evaluated and compared to several existing tools using independent datasets. Results: GBMPurity outperformed existing tools, achieving a mean absolute error of 0.15 and a concordance correlation coefficient of 0.88 on validation datasets. We demonstrate the utility of GBMPurity through inference on bulk RNA-seq samples and observe reduced purity of the proneural molecular subtype relative to the classical, attributed to the increased presence of healthy brain cells. Conclusions: GBMPurity provides a reliable and accessible tool for estimating tumor purity from bulk RNA-seq data, enhancing the interpretation of bulk RNA-seq data and offering valuable insights into GBM biology. To facilitate the use of this model by the wider research community, GBMPurity is available as a web-based tool at: https://gbmdeconvoluter.leeds.ac.uk/.